How to use Technologies offered

A search for a cancer, preclinical stage, synthetic opportunity would use the selection "Therapeutics, Diagnostics" in 'Sector', 'Cancerous, neoplasmatic' in 'Disease Category', 'Drugs, Small Molecule' in 'Technology' and 'Preclinical' in 'Development Stage'.

Selection of 'Enabling Technology, Platform Technology' in 'Sector' will identify all kinds of research technologies that can be used in more areas of life sciences than pharmaceuticals only.

Each technology profile gives the name of a company or academic institute as source of the offer, and a link allowing to contact the potential licensor. In most cases a profile includes a pdf covering the available non-confidential information as well as detailed contact data.

Registered users can create non-public notifications profiles which will inform them about new 'Technologies Offered' entries fitting their needs as specified. In addition these profiles allow them to filter the available information more comfortably.


Egr-1 Luciferase Mouse Model - monitor and quantify Egr-1 activity in the living organism

Organization name

Max-Planck-Innovation GmbH



The zinc finger transcription factor Egr-1 (Early growth response 1) is central to several growth factors and represents an important activator of target genes not only involved in physiological processes like embryogenesis and neonatal development, but also in a variety of pathophysiological processes, for example atherosclerosis and cancer. Current options to investigate its transcription and activation in vivo are end-point measurements that do not provide insights into dynamic changes in the living organism.


Our researchers developed a transgenic mouse (Egr-1-luc) in which the luciferase reporter gene is under control of the murine Egr-1 promotor providing a versatile tool to study the time course of Egr-1 activation in vivo. In neonatal mice, bioluminescence imaging revealed a high Egr-1 promotor activity reaching basal levels three weeks after birth with activity at snout, ears and paws. Using a model of partial hepatectomy our researchers could show that Egr-1 promotor activity and Egr-1 mRNA levels were increased in the regenerating liver. In a model of wound healing it has been demonstrated that Egr-1 promotor activity was upregulated at the site of injury.

Taken together, a transgenic mouse model has been developed that allows real time in vivo imaging of the Egr-1 promotor activity. The ability to monitor and quantify Egr-1 activity in the living organism may facilitate a better understanding of Egr-1 function in vivo. The transgenic mouse model Egr-1-luc is available for licensing.


Live in vivo imaging of Egr-1 promoter activity during neonatal development, liver regeneration and wound healing Philipp Dussmann, Judith I Pagel, Sabina Vogel, Terese Magnusson, Rene Zimmermann, Ernst Wagner, Wolfgang Schaper, Manfred Ogris and Elisabeth Deindl, BMC Developmental Biology, 11:28 (20 May 2011)

To view the contact information, attachments and url of this profile you have to login into your account or register a new account: Login Register

Your feedback

Please click here to log in to view the complete profile.


latest entries